A Phase IIa, Randomised, Multi-Centre, Double-Blind, Placebo-Controlled, 3 Periods, Crossover Study to Investigate the Efficacy, Pharmacokinetics, Safety and Tolerability of Inhaled AZD8871 Administered Once Daily for 2 Weeks in Patients With Moderate to Severe COPD.

Trial Profile

A Phase IIa, Randomised, Multi-Centre, Double-Blind, Placebo-Controlled, 3 Periods, Crossover Study to Investigate the Efficacy, Pharmacokinetics, Safety and Tolerability of Inhaled AZD8871 Administered Once Daily for 2 Weeks in Patients With Moderate to Severe COPD.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 May 2017

At a glance

  • Drugs AZD 8871 (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Proof of concept; Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 16 May 2017 Status changed from recruiting to active, no longer recruiting.
    • 11 Apr 2017 Planned End Date changed from 1 Jul 2017 to 18 Aug 2017.
    • 11 Apr 2017 Planned primary completion date changed from 1 Jul 2017 to 18 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top